文献速递心力衰竭与心肌病

利钠肽与射血分数保留心衰心血管预后关联:TOPCAT随机临床试验二次分析

Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该研究为TOPCAT试验二次分析,纳入美洲地区1057例有症状且左室射血分数≥45%的射血分数保留心衰(HFpEF)患者,评估利钠肽(NP)在6个临床亚组中的分布及预后意义。结论提示NP仍是HFpEF重要预后标志物,但单一绝对阈值可能导致某些亚组入组不足。

要点

  • NP水平在年龄、种族、肥胖、肾功能和房颤亚组间差异可达0.5个标准差。
  • NP每升高1个标准差,主要复合终点风险增加36%(校正HR 1.36,95%CI 1.22-1.54)。

核心结论

  • 利钠肽仍是HFpEF重要的预后生物标志物,即使在NP水平倾向较低的亚组中也是如此。
  • 当代HFpEF试验采用单一绝对NP阈值可能导致某些人口学和临床亚组代表性不足。

研究设计与样本

  • TOPCAT试验的二次分析,评估NP在6个亚组中的分布和预后意义。
  • 纳入美洲地区1057例成年患者(占60%),有症状心衰且左室射血分数≥45%,基线有NP可用。
  • 暴露为对数转换并标准化的NP(每1个标准差,z评分),评估6个亚组:年龄( cutoff 70岁)、黑人种族、BMI( cutoff 30 kg/m2)、腰围(男性 cutoff 102 cm,女性 cutoff 88 cm)、eGFR( cutoff 60 mL/min/1.73 m2)和房颤病史。
  • 主要结局为心血管死亡、心衰住院或猝死复苏的复合终点,平均(SD)随访2.4(1.5)年。

主要发现

  • 1057例参与者平均(SD)年龄72(10)岁,183例(17.3%)为黑人,平均(SD)BMI 33.4(8.6)kg/m2,平均(SD)eGFR 64.6(21.8)mL/min/1.73 m2,472例(45%)有房颤病史。
  • 中位B型NP(n=698)浓度为257(IQR 149-443)ng/L,中位N末端B型NP前体(n=359)浓度为959(IQR 554-2015)ng/L。
  • NP浓度在6个亚组内差异可达0.5个标准差,在年龄较大、非黑人种族、较低BMI、较低腰围、较低eGFR和有房颤病史的患者中更高。
  • 在TOPCAT美洲地区(n=1767)中,791例(45%)因NP升高符合入选标准(而非心衰住院史);该比例在黑人种族、年龄<70岁和BMI≥30 kg/m2亚组中分别为31%(93/302)、34%(258/760)和39%(443/1144)。

关键数值与推荐

  • NP升高定义为每1个标准差增加(对数转换并标准化)。
  • 主要结局复合终点包括心血管死亡、心衰住院或猝死复苏。
  • 亚组 cutoff 值:年龄70岁、BMI 30 kg/m2、腰围男性102 cm/女性88 cm、eGFR 60 mL/min/1.73 m2。

临床怎么用

  • NP可用于HFpEF患者风险分层,即使患者属于NP水平倾向较低的亚组(如肥胖、黑人种族)。
  • 在解读NP水平时应考虑年龄、种族、肥胖、肾功能和房颤状态对NP浓度的影响。
  • 临床试验入选标准若采用单一绝对NP阈值,可能需警惕对某些亚组的代表性不足。

局限性

  • 本研究为TOPCAT试验的二次分析,结果需在其它人群中验证。
  • 仅纳入美洲地区有基线NP数据的患者,可能存在选择偏倚。
  • NP检测类型(BNP或NT-proBNP)因患者而异,可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Contemporary clinical trials of heart failure with preserved ejection fraction (HFpEF) apply natriuretic peptide (NP) thresholds to identify patients who are more likely to have the disease of interest and to enrich the baseline risk of the enrolled cohort. OBJECTIVE: To determine whether age, race/ethnicity, obesity, renal function, and atrial fibrillation (AF) affect the levels of NPs in HFpEF and whether the prognostic significance of NPs varies in these clinically important subgroups. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT) evaluated the distribution and prognostic significance of NPs across 6 subgroups comprising 1057 adult patients (60%) in the Americas region of TOPCAT with symptomatic heart failure (HF) and a left ventricular ejection fraction of 45% or more with available NPs at baseline. EXPOSURES: Natriuretic peptides were log-transformed and standardized (expressed per 1 SD, z score) and assessed in 6 subgroups: age (cutoff, 70 years), black race, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared; cutoff, 30 kg/m2), waist circumference (cutoff, 102 cm for men, 88 cm for women), estimated glomerular filtration rate (cutoff, 60 mL/min/1.73 m2), and a history of AF. MAIN OUTCOMES AND MEASURES: Time to composite cardiovascular death, hospitalization for HF, or aborted cardiac arrest at mean (SD) 2.4-year (1.5) follow-up. RESULTS: Of 1057 participants, the mean (SD) age was 72 (10) years, 183 (17.3%) were black, the mean (SD) BMI was 33.4 (8.6) kg/m2, the mean (SD) estimated glomerular filtration rate was 64.6 (21.8) mL/min/1.73 m2, and 472 (45%) had a history of AF. Median B-type NP (n = 698) and N-terminal pro-B-type NP concentrations (n = 359) were 257 (interquartile range, 149-443) ng/L and 959 (interquartile range, 554-2015) ng/L, respectively. Natriuretic peptide concentrations varied by up to 0.5 SD within the 6 subgroups, being higher in older patients with nonblack race, a lower BMI, a lower waist circumference, a lower estimated glomerular filtration rate, and a history of AF. Elevated NP levels (per 1-SD increase) were independently associated with an increased risk of the primary outcome (adjusted hazard ratio, 1.36; 95% CI, 1.22-1.54; P < .001) consistently across all investigated subgroups (interaction P > .05). In TOPCAT Americas (n = 1767), 791 (45%) were enrolled based on elevated NP levels as the qualifying criterion (as opposed to a history of HF hospitalization). This proportion was 31% (93 of 302), 34% (258 of 760), and 39% (443 of 1144) for black race, younger than 70 years, and a BMI of 30 kg/m2 or greater, respectively. CONCLUSIONS AND RELEVANCE: Natriuretic peptides remain important biomarkers of prognosis in HFpEF, even in subgroups who tend to have lower NP levels. A single, absolute NP threshold for inclusion in contemporary HFpEF trials may lead to an underrepresentation of certain demographic and clinical subgroups. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00094302.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Myhre PL, Vaduganathan M, Claggett BL, et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 30140899. doi:10.1001/jamacardio.2018.2568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。